



FDA Clears VRIxp, a Non-Invasive, Radiation-Free Pulmonary Imaging System, for Aiding in Diagnosis and Patient Management

Deep Breeze™ VRIxp™ Pulmonary Imaging System Records & Monitors Lung Sounds

OR-AKIVA, Israel (May 30, 2010)—Deep Breeze™, the innovative company that has developed the Vibration Response Imaging (VRI™) technology, announced today that the U.S. Food and Drug Administration (FDA) granted 510K marketing clearance for the VRIxp™, previously cleared for recording and monitoring lung sounds, as an Aid in Diagnosis and patient management when interpreted by physicians with general medical training and experience.

“The new FDA approval is the result of close to 10 years of research and development and clinical work, enabling adding to the visual presentation of VRI images, objective quantitative measures, amongst which is the automatic detection of adventitious lung sounds such as crackles and wheezes. This presents the physicians with a complementary tool to help in diagnosing respiratory disorders.” said Michael Nagler, PhD, CEO of Deep Breeze™. “The FDA clearance for Aid in Diagnosis represents a significant milestone for the Company enabling positioning VRI™ technology as an additional and novel diagnostic aid in the physician’s toolbox, alongside other imaging modalities such as XRay and Ultrasound. This new clearance opens the way for the VRIxp™ system to be sold for use in a wide range of applications.”

The non-invasive and radiation-free imaging system records lung sounds created by the breathing process using an array of proprietary, patent protected sensors applied to the patient’s back. The system then uses proprietary algorithms to convert these data into dynamic images presenting lung function and into quantitative information that the physician can use in making treatment decisions. Changes in tissue composition or alteration in airflow impact the characteristics of sounds generated by lung tissue vibrations and, subsequently, affect how the VRIxp™ images and quantitative data appear on the system’s computer screen. Comparison of repeated images and quantitative lung sounds data provide information about changes in the lungs over time or following treatment.

“The radiation-free VRIxp™ procedure takes only minutes in a physician’s office and may be performed repeatedly for continuous monitoring and now also to help in diagnosing patients with respiratory diseases. Results are delivered to the physician immediately and can be stored in a system database for future use. The technology is being used at more than 150 sites, many at leading institutions all over the world in a variety of applications. More than 5,000 patients worldwide have been recorded to date, without any adverse events.” comments David Barton, President of Deep Breeze, Inc., the US arm of the company tasked with commercialization of the product.

About Deep Breeze™

Founded in 2001, Israel-based Deep Breeze is a privately-held medical device company that is providing advanced pulmonary imaging with its proprietary patented technology, Vibration Response Imaging (VRI). The Company has conducted clinical studies globally to evaluate VRI efficacy in fields such as: general pulmonology, COPD, CHF, asthma, interventional pulmonology, lung cancer, lung transplant and critical care patient management, and is continuing to invest in clinical research for the purpose of expanding its product offering including now —home use for monitoring patients with chronic disease.

For additional information, please visit our website: www.deepbreeze.com or contact us:

Deep Breeze

Tel: +1 262-719-2056

Email: Jackie.Stetina@deepbreeze.com

Tel: +972-(0)4-656 6650

Email: Doran.Rozen@deepbreeze.com